Ugichem GmbH of Austria, which has developed a new antisense drug technology platform, has raised €2.25 million from public and private investors to advance preclinical drug candidates for immune-mediated inflammatory diseases. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
